Condition: PIPO · Sponsor: University Hospital, Grenoble
The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.
This description comes directly from the study's public registry record.
John Rendu, Dr · 0476765573 · jrendu@chu-grenoble.fr
Mandy Leger · 0476768410 · mleger@chu-grenoble.fr
Always discuss trial participation with your own doctor first.
| Phymedexp Inserm U1046 - Cnrs Umr 9214 | Montpellier, France | Recruiting |
| Tens - Inserm Un Umr 1235 | Nantes, France | Recruiting |
| AP-HP Hôpital Robert Debré | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06687564